ALLO-605

N/A

Report date: 2024/06/29 20:00:09

Base Information

Drug NameALLO-605
Drug Alias NameALLO-605 TurboCAR™ (Allogene Therapeutics)Allogeneic Turbo Chimeric Antigen Receptor (Turbocar) T Cells Targeting B Cell Maturation Antigen (Allogene Therapeutics)ALLO-605ALLO605
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein inhibitorsImmunologic cytotoxicityT lymphocyte replacements
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCellectis SaOverland Pharmaceuticals (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOverland Pharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesAllogene Therapeutics Inc
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A